Recent advances in pathophysiology, diagnosis and management of hepatorenal syndrome: A review

Table 4 Results of recent meta-analyses comparing terlipressin to other vasoconstrictor therapies in hepatorenal syndrome with acute kidney injury

Ref.	Study design	Number of studies	HRS reversal	Mortality benefit	Data quality
Facciorusso et al[76], 2017	Meta-analysis	13	Same as NE; better than Alb+OCT; better than Alb+MID+OCT	Possible short-term benefits	Very low to low
Isralesen et al[77], 2017	Meta-analysis	10	Same as NE; better than Alb+OCT; better than Alb+MID+OCT	No difference	Very low to low
Nanda et al[78], 2018	Meta-analysis	13	Same as NE; better than Alb+OCT; better than Alb+MID+OCT	No difference	Poor to good
Wang et al[79], 2018	Meta-analysis	18	Same as NE; better than Alb+OCT; better than Alb+MID+OCT	Confers short-term benefits	Low to high
Best et al[80], 2019	Meta-analysis	25	Same as NE; better than Alb+OCT; better than Alb+MID+OCT	No difference	Very low to low

Alb: Albumin; HRS: Hepatorenal syndrome; HRS-AKI: Hepatorenal syndrome with acute kidney injury; MID: Midodrine; NE: Norepinephrine; OCT: Octreotide.